西格玛-1受体作为糖尿病病的新疗法标
Dora B Balogh1,2, Judit Hodrea1,2, Adar Saeed1,2
1MTA-SE Lendület "Momentum" Diabetes Research Group, 1083 Budapest, Hungary.
International journal of molecular sciences
|January 8, 2025
概括
通过激活西格玛-1受体 (S1R),黄素 (FLU) 显示出减缓糖尿病病 (DKD) 进展的前景. 这项研究发现,FLU改善了功能,并通过向炎症,缺氧和纤维化来减少损伤.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 糖尿病病 (DKD) 是慢性病的主要原因,有效治疗方法有限.
- 目前的治疗方法无法阻止DKD的进展,因此需要新的治疗策略.
- 随着fluvoxamine (FLU) 的西格玛-1受体 (S1R) 激活,之前已经证明了对急性损伤的保护.
研究的目的:
- 在糖尿病病 (DKD) 的大鼠模型中研究黄 (FLU) 的潜在保护作用.
- 探索FLU作用背后的机制,重点关注炎症,缺氧和纤维化途径.
主要方法:
- 在Wistar大鼠中使用链毒素诱导了DKD,随后进行了为期七周的FLU治疗.
- 评估了功能,代谢参数和组织学.
- 在体外研究中使用了人类近接管状细胞和老鼠纤维细胞来研究FLU对炎症,缺氧和纤维化的影响.
主要成果:
- 在糖尿病大鼠中,富洛胺 (FLU) 治疗改善了功能,并显著减少了淋巴细胞损伤和管间纤维化.
- 通过降低TLR4,IL6和NFKB1基因表达,FLU减轻了炎症.
- FLU调节了细胞对管状缺氧的反应,并抑制了TGF-β1诱导的纤维化过程.
结论:
- 随着fluvoxamine (FLU) 激活西格玛-1受体 (S1R),在糖尿病病 (DKD) 中显示出显著的保护作用.
- FLU通过调节炎症,缺氧和纤维化所涉及的关键通路来改善DKD.
- 激活S1R是一种有希望的治疗点,可以减缓DKD的进展并保持功能.
相关概念视频
01:24Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
01:28Insulin: The Receptor and Signaling Pathways
1.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.1K
01:15G Protein-coupled Receptors
11.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.3K
01:33Hormonal Regulation
32.9K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381